Status:
COMPLETED
Study Evaluating the Safety, Tolerability, and Efficacy of Lecozotan SR in Outpatients With Alzheimer's Disease
Lead Sponsor:
Pfizer
Conditions:
Alzheimer Disease
Eligibility:
All Genders
50+ years
Phase:
PHASE2
PHASE3
Brief Summary
The purpose of the study is to determine the safety, tolerability, and efficacy of 3 doses of lecozotan in combination with a cholinesterase inhibitor in patients with mild to moderate Alzheimer's dis...
Eligibility Criteria
Inclusion
- Diagnosis of probable Alzheimer's disease
- Current use of cholinesterase inhibitor
- Able to give signed and dated informed consent and lives with appropriate caregiver at home or in community dwelling with caregiver accompanying patient to all visits and visiting patient at least daily for duration of the study
Exclusion
- Significant neurological disease other than AD
- Diagnosis of major depression
- History of stroke or other heart disease
Key Trial Info
Start Date :
March 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2008
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT00277810
Start Date
March 1 2006
End Date
June 1 2008
Last Update
July 7 2020
Active Locations (83)
Enter a location and click search to find clinical trials sorted by distance.
1
Phoenix, Arizona, United States, 85013
2
Tucson, Arizona, United States, 85741
3
Costa Mesa, California, United States, 92626
4
Fresno, California, United States, 93720